

**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**"Muscarinic Acetylcholine Receptor Antagonists"**

the specification of which (check one)

is attached hereto.

was filed on **16 July 2004** as Serial No. **PCT/US2004/023042**  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

| Prior Foreign Application(s)<br>Number | Country | Filing Date | Priority Claimed |
|--|---------|-------------|------------------|
|--|---------|-------------|------------------|

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

| Application Number | Filing Date         |
|--------------------|---------------------|
| <b>60/488,061</b>  | <b>17 July 2003</b> |

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

| Serial No. | Filing Date | Status |
|------------|-------------|--------|
|------------|-------------|--------|

Address all correspondence and telephone calls to **Customer Number 20462**

Soma G. Simon, GlaxoSmithKline, CIP-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5019.

I hereby appoint the practitioners associated with the Customer Numbers provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith Customer Number 20462 and Customer Number 23347.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Kristen E. BELMONTE

Inventor's Signature: Kristen E. BELMONTE

Date: 4 Aug 2004

Residence: King of Prussia, PA 19406

Citizenship: United States of America

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Jakob BUSCH-PETERSEN

Inventor's Signature: Jakob Busch-Petersen


Date: 8/11/04

Residence: King of Prussia, PA 19406

Citizenship: Denmark

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Dramane I. LAINE

Inventor's Signature: 

Date: 04 August 2004

Residence: King of Prussia, PA 19406

Citizenship: France

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Michael R. PALOVICH

Inventor's Signature: 

Date: 8/4/04

Residence: King of Prussia, PA 19406

Citizenship: United States of America

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

A/D 581-40

ASSIGNMENT

WHEREAS we, Kristen E. BELMONTE of King of Prussia, PA 19406, a citizen of United States of America; Jakob BUSCH-PETERSEN of King of Prussia, PA 19406, a citizen of Denmark; and Dramane I. LAINE of King of Prussia, PA 19406, a citizen of France; Michael R. PALOVICH of King of Prussia, PA 19406, a citizen of United States of America; have made an invention entitled:

"Muscarinic Acetylcholine Receptor Antagonists"

for which on an even date we executed an application for Letters Patent of the United States under 35 U.S.C. §111(a), executed an application for Letters Patents of the United States under 35 U.S.C. §371, or filed a Provisional application under 35 U.S.C. §111(b):

NOW, THEREFORE, in return for valuable consideration paid to us by Glaxo Group Limited, a corporation organized under the laws of the United Kingdom and having its principal place of business at Glaxo Wellcome House, Berkeley Ave, Greenford, Middlesex UB6 0NN Great Britain, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, we do hereby assign unto the said Glaxo Group Limited, its successors and assigns, the entire right, title and interest in and to the said invention, executed under 35 U.S.C. §111(a), 35 U.S.C. §371, or filed under 35 U.S.C. §111(b) application, and from which priority may be claimed from one or more 35 U.S.C. §111(b) applications, or any division, continuation and continuation-in-part of said application, and all Letters Patent of the United States and all foreign countries to be obtained therefor;

We further assign to the said Glaxo Group Limited the right, optionally in its own name or in the names of its related companies, to apply for, obtain and maintain in all countries foreign to the United States, patent and/or Utility Model applications for said invention, including the full right to claim for any such application the benefits of any priority rights based on said executed United States application;

And we agree to execute further instruments (including provisional, divisional, continuation, continuation-in-part or reissue applications or other instruments) proper to effectuate the premises, this agreement to be binding upon our heirs, executors and administrators;

And we request the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue Letters Patent in accordance herewith.

Kristen E. BELMONTE  
Kristen E. BELMONTE

Date: 4 Aug 2004

Jakob BUSCH-PETERSEN  
Jakob BUSCH-PETERSEN

Date: 8/4/04

Dramane I. LAINE  
Michael R. PALOVICH  
Michael R. PALOVICH

Date 8/4/04

Date 8/4/04